News

Meet the neurosurgeon-CEO taking on cancer drug resistance

John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them.
Written byAndrea Corona
| 3 min read
hands holding

Split between the operatin groom, the lab and the board room, John Yu finds each role feeding the others.

ISTOCK.COM/ EB_RA

Register for free to listen to this article
Listen with Speechify
0:00
3:00

DDN caught up with John Yu, the Kairos Pharma CEO about the mechanism his company is betting on and how he splits his time between the operating room and the bench.

A neurosurgeon at Cedars-Sinai Medical Center who still runs an NIH-funded lab there, Yu founded Kairos Pharma to chase a problem he kept seeing in his own patients: a cancer drug works well for months, sometimes a couple of years, and then the tumor comes back anyway.

"I see patients do very well for about a year, maybe six months on a therapeutic, but they always relapse and their tumor almost always comes back within that period of time," Yu told DDN. That pattern, repeated across tumor types, pushed him to focus Kairos on resistance itself rather than on building another drug meant to outcompete existing therapies.

His comparison point is HIV. Once a rapidly fatal diagnosis, it became a chronic, manageable condition once clinicians learned to rotate therapies as resistance emerged. Yu wants to do the same for cancer: not necessarily cure it, but keep extending the window before a tumor stops responding.

Why CD105

Kairos's lead candidate, ENV-105, targets CD105, a protein Yu's team linked to a specific resistance mechanism. When cancer drugs put pressure on a tumor, CD105 activates BMP4 (Bone Morphogenetic Protein 4) signaling, which pushes tumor cells toward a more stem-cell-like state. That shift is what makes them harder to kill: Stem-like cells are built to survive stress, including chemotherapy and radiation.

Continue reading below...
A 3D illustration of two sphericaA 3D illustration of two spherical cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.l cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.
Application NoteRevealing cell-cell interactions in immuno-oncology
Imaging-enabled flow cytometry helps distinguish biologically relevant cell-cell interactions from coincident events to support immunotherapy research.
Read More

"As tumors become more stem cell-like, they become more resistant to the toxins in the environment," Yu said, drawing a parallel to normal stem cells, which are similarly built to withstand external damage in order to keep replenishing an organ's cell types.

In prostate cancer, one downstream effect of that resistance is the emergence of AR-V7, (androgen receptor splice variant) a truncated androgen receptor variant that lets tumor cells keep growing without needing the hormone signal that anti-androgen drugs are designed to block. Yu said that when CD105 signaling is disrupted, AR-V7 expression drops and tumor cells become more differentiated, potentially restoring sensitivity to anti-androgen therapy.

That mechanism is now in two clinical programs. A Phase 2 trial pairs ENV-105 with the anti-androgen apalutamide in metastatic castration-resistant prostate cancer, and a Phase 1 trial combines it with the EGFR inhibitor osimertinib in EGFR-mutated non-small cell lung cancer. Kairos has reported that an interim analysis of the prostate cancer trial showed clinical benefit in 86 percent of treated patients, with responders remaining progression-free for at least four months and about half beyond a year. That figure comes from a small interim readout — roughly nine evaluable patients — and hasn't gone through peer review, so it should be read as an early, company-reported signal rather than a confirmed efficacy result.

Betting on one pathway, multiple diseases

Running two trials in different cancers at once is an unusual resource commitment for a small, clinical-stage company. Yu's rationale is that both programs are testing the same underlying mechanism rather than two unrelated bets. Kairos has also seen the CD105/BMP4 pathway show up in preclinical work in colon and breast cancer, and Yu said the company is in early discussions with pharmaceutical partners about whether disrupting that pathway could extend the effectiveness of radioligand therapies, an emerging drug class in prostate cancer.

A second internal candidate, ENV-205, targets a different resistance mechanism tied to mitochondrial DNA and chemotherapy resistance.

Leaning on the academic connection

Kairos runs on a structure Yu described as deliberately academic. Rather than paying for commercial contract research organizations (CRO), the company is working to establish a consortium of academic medical centers, including Cedars-Sinai, Mayo Clinic, Cleveland Clinic and Stanford University, that would run trials under a single institutional review board. Yu said the goal is to start trials faster and at lower cost than a traditional commercial CRO model would allow, while giving Kairos direct access to a large academic patient population.

For Yu, the arrangement reflects how he sees his own career: split between the operating room, the lab and the boardroom, with each role feeding the others. "It's all part of the same idea, of this cycle between academics and biotech and pharma to develop therapies for patients," he said.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Headshot

    Andrea Corona is the senior editor at Drug Discovery News, where she leads daily editorial planning and produces original reporting on breakthroughs in drug discovery and development. With a background in health and pharma journalism, she specializes in translating breakthrough science into engaging stories that resonate with researchers, industry professionals, and decision-makers across biotech and pharma. Her work blends investigative reporting with a deep understanding of the drug development pipeline, and she is particularly interested in stories at the intersection of science, innovation and technology.

    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.